Arthritis is the leading cause of disability in adults in the U.S. Understandably, this has led to much concern about the future of arthritis treatment.
An OMRF discovery could potentially open the door for the first drug option to treat age-related muscle weakness and atrophy.
The grant will provide Bob Axtell with $2.8 million to study NMO and investigate its similarities to other autoimmune diseases, particularly MS.
For Mary Long, the answer to her pain may, literally, be right around the corner.